

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Proflavine and zinc chloride “team chemistry”: combining antibacterial agents via solid-state interaction

This is the final peer-reviewed author’s accepted manuscript (postprint) of the following publication:

Published Version:

Fiore C., Shemchuk O., Grepioni F., Turner R.J., Braga D. (2021). Proflavine and zinc chloride “team chemistry”: combining antibacterial agents via solid-state interaction. *CRYSTENGCOMM*, 23(25), 4494-4499 [10.1039/d1ce00612f].

Availability:

This version is available at: <https://hdl.handle.net/11585/855179> since: 2022-02-10

Published:

DOI: <http://doi.org/10.1039/d1ce00612f>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

Fiore, C., Shemchuk, O., Grepioni, F., Turner, R.J., Braga, D., 2021. Proflavine and zinc chloride “team chemistry”: combining antibacterial agents via solid-state interaction. CrystEngComm 23, 4494–4499.

The final published version is available online at:
<https://doi.org/10.1039/D1CE00612F>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.


This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

CrystEngComm

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: C. Fiore, O. Shemchuk, F. Grepioni, R. J. Turner and D. Braga, *CrystEngComm*, 2021, DOI: 10.1039/D1CE00612F.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

ARTICLE

Proflavine and zinc chloride “team chemistry”: Combining antibacterial agents via solid-state interaction.

Cecilia Fiore,^a Oleksii Shemchuk,^a Fabrizia Grepioni,^a Raymond J. Turner^{*,b} and Dario Braga^{*,a}

Received 00th January 20xx,
Accepted 00th January 20xx


DOI: 10.1039/x0xx00000x

Co-crystallization of the antibacterial agent proflavine (PF) with the inorganic salt ZnCl_2 by mechanochemical and solution methods results in the formation of the novel compounds $\text{ZnCl}_3(\text{HPF})$ (**1**) and $[\text{HPF}]_2[\text{ZnCl}_4]\cdot\text{H}_2\text{O}$ (**2**), both containing the proflavinium cation (HPF^+). Both compounds show a 50-125% enhanced antimicrobial activity with respect to the reference standard of AgNO_3 and a 25-50% enhancement to the behaviour of the separate components against pathogen indicator strains of *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Escherichia coli*. In terms of crystal structure both compounds $\text{ZnCl}_3(\text{HPF})$ and $[\text{HPF}]_2[\text{ZnCl}_4]\cdot\text{H}_2\text{O}$ are characterized by extensive π -stacking interactions between the proflavine moieties. The same interaction is predominant in the previously unknown crystal structures of neutral proflavine (PF), as well as in that of its dihydrated monochloride salt, $[\text{HPF}]\text{Cl}\cdot 2\text{H}_2\text{O}$, which are also described in this paper.

Introduction

Antimicrobial resistance (AMR)¹ is rapidly developing as the major health problems of our time, mainly caused by the abuse of antibiotics to control infections in humans and animals.² Most of the common pathogenic strains already have antibiotic-resistant genes and, presumably, more antibiotic-resistant pathogens will emerge in the future.³ The quest for new antimicrobial agents can nowadays rely on the important conceptual tools provided by crystal engineering⁴ namely the possibility of associating within the same crystalline material two or more components⁵ via co-crystallization. As a matter of fact, co-crystallization is being actively explored in the pharmaceutical field,⁶ since the association of an active ingredient and a coformer, which, in turn, can also be an active molecule, can generate new pharmaceuticals or alter significantly the physico-chemical and pharmacokinetic properties of known ones.⁷ In the quest for a crystal engineering based answer to the AMR problem, we have recently shown that co-crystallization of the antibacterial compounds proflavine⁸ and methyl viologen,⁹ with metal salts, such as CuCl , CuCl_2 and AgNO_3 is a viable, eco-friendly, and inexpensive way to obtain new materials with enhanced antibacterial properties.¹⁰ Analogous co-crystallization approach has been used to prepare new antibacterial active associations of known antibiotics, such as ciprofloxacin, with natural antimicrobials, such as thymol and carvacrol.¹¹ Based on the same approach a multicomponent solid consisting of an antibacterial

(norfloxacin) and an antimicrobial (sulfathiazole) have been recently reported by Desiraju et al.¹² showing enhancement of in vitro biological properties and improved physicochemical behaviour. Beyond organic antimicrobial molecules, metal-based antimicrobials are of great interest as new means of dealing with the AMR threat.^{13,14} Silver, zinc, copper and others have been used for millennia as antimicrobial agents.¹⁵ However, the combination of metals with organic antimicrobials as metal-coordinated ligands and/or in co-crystals may represent an alternative resource in the quest for new and diverse solutions.¹⁶ In this work we apply a crystal engineering approach to the preparation, characterization and antimicrobial activity evaluation of two novel compounds obtained from the known antibacterial agent proflavine (see Scheme 1 for neutral proflavine, PF) which is reacted as its hydrochloride proflavinium cation (HPF^+) with zinc chloride. Depending on the stoichiometric ratio between (PFH^+) and zinc chloride and on the preparative conditions the new compounds $\text{ZnCl}_3(\text{HPF})$ (**1**) and $[\text{HPF}]_2[\text{ZnCl}_4]\cdot\text{H}_2\text{O}$ (**2**) have been obtained by both solution and mechanochemical methods and characterized by X-ray diffraction, DSC and TGA.



Scheme 1. Neutral PF and monoprotonated proflavine HPF used in this work.

The structure of **1** has been determined from powder diffraction data, as it proved impossible to grow single crystals, while that of **2** has been determined from single-crystal X-ray data. Correspondence between the bulk mechanochemical products and the structures of **1** and **2** has been verified by comparing observed and calculated X-ray powder diffraction

^a Dipartimento di Chimica “Giacomo Ciamician”, Università di Bologna, Via Selmi, 2 – 40126 Bologna – Italy.

^b Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta T2N 1N4,

Electronic Supplementary Information (ESI) available: single crystal and powder X-ray diffraction data, TGA and DSC. See DOI: 10.1039/x0xx00000x

patterns. The mono-hydrate nature of **2** has been ascertained by TGA. The antimicrobial activity of **1** and **2** has been tested against the pathogen indicator strains *Pseudomonas aeruginosa* ATCC27853, *Staphylococcus aureus* ATCC25923, and *Escherichia coli* ATCC 25922. To evaluate the efficacy of the antimicrobials, we have used the established method of measuring a zone of growth inhibition and contact killing using compound impregnated antimicrobial susceptibility filter disk. In this paper we also report the structural characterization of two novel forms of proflavine, namely the anhydrous proflavine (PF), obtained by dehydration of proflavine monohydrate PF·H₂O (CSD refcode PROFLV¹⁷), and that of its hydrochloride salt, [HPF]Cl·2H₂O, the monoprotonated form of the known dichloride salt [H₂PF]Cl₂·2H₂O (CSD refcode PROFLC¹⁸). Despite the different nature of the four compounds, the neutral organic molecule (PF), a hydrated salt [HPF]Cl·2H₂O, a coordination compound between PF and zinc-chloride **1** and a salt **2**, all these crystals share the common feature of extensive π -stacking and of herring-bone interactions between the proflavine/proflavinium moieties.

Experimental

Materials and methods

All reagents and solvents used in this work were purchased from Sigma-Aldrich and used without further purification.

Preparation of PF·H₂O. Commercial [HPF]₂[SO₄]_xH₂O (1 g) was dissolved in 25 mL of water and 3.10 g (0.077 mol) of NaOH was added to the solution, yielding PF·H₂O as a crystalline powder, which was filtered and washed several times with water. The experimental X-ray powder pattern of the product matched the one calculated on the basis of single crystal data for PROFLV (fig. SI-1). A sample of polycrystalline PF·H₂O was analyzed via Hot Stage Microscopy (HSM), using a Linkam TMS94 device connected to a Linkam LTS350 platinum plate and an Olympus optical microscope; heating rate of 10 °C·min⁻¹ was applied. Crystal growth of anhydrous proflavine was observed on the original powder at ca. 100 °C, concomitantly with the dehydration process of PF·H₂O. The sample was cooled down to room temperature and the yellow single crystals were structurally characterized analyzed via X-ray diffraction.

Synthesis of PF anhydrous. The anhydrous phase of PF was obtained by thermal treatment in oven for 20 min at 85 °C. The product was characterized by X-ray powder diffraction and the pattern compared with the one calculated from single crystals of PF anhydrous. Single crystals of anhydrous proflavine were obtained directly upon dehydration of PF·H₂O under the microscope during hot-stage heating to 100 °C.

Solution synthesis of ZnCl₃(HPF) (1**) (PF·H₂O: ZnCl₂ = 1:1).** A solution of PF·H₂O (113.62 mg, 0.5 mmol) in HCl 0.1 M (2.5 mL, 0.25 mmol) was added to a solution of ZnCl₂ (68.14 mg, 0.5 mmol) in water (1 mL). A crystalline powder was recovered after slow evaporation of the solvent and used for structural characterization.

Solution synthesis of [HPF]₂[ZnCl₄]·H₂O (2**) (PF·H₂O : ZnCl₂ = 2:1).** A solution of PF·H₂O (113.62 mg, 0.5 mmol) in HCl 0.1 M (5 mL, 0.5 mmol) was added to a solution of ZnCl₂ (34.07 mg,

0.25 mmol) in water (0.5 mL). A crystalline powder was recovered after slow evaporation of the solvent. Single crystals of **2** were recovered and used for diffraction experiments (see below). Serendipitously, single crystals of [HPF]Cl·2H₂O were also recovered from one of the crystallization batches and submitted to X-ray diffraction.

Solid-state synthesis of ZnCl₃(HPF) (1**).** Crystalline **1** was also obtained by kneading 1:1 stoichiometric amount of [HPF]Cl (obtained by reacting proflavine free base with HCl 0.1M and drying in rotavapor - purity of the product was checked by solution NMR) and ZnCl₂, in the presence of 2-3 drops of acetone, for 1 hour in a Retsch MM200 Mixer Mill, operated at a frequency of 15 Hz, with 5 mL agate jars and 2 balls of 5 mm diameter. The same reaction in 2:1 stoichiometric ratio still yielded compound **1**.

Powder X-ray diffraction. For phase identification purposes, room temperature X-ray powder diffraction (XRPD) patterns were collected on a PANalytical X'Pert PRO automated diffractometer equipped with an X'celerator detector in the 2 θ range 3–40° (step size 0.011, time/step 50 s, Vx4 40x40).

For structural characterization of ZnCl₃(HPF) (**1**) from powder data, a room temperature X-ray diffraction pattern was collected in transmission geometry on a PANalytical X'Pert PRO automated diffractometer, equipped with Focusing mirror and Pixcel detector, in the 2 θ range 3–60° (step size 0.0130°, time/step 118.32 s, Vx4 40kV x 40mA). To improve the quality of the obtained XRPD patterns 3 repetitions were performed and the scans were merged. The compound was indexed in the triclinic P-1 space group with the auto-indexing module of N-TREOR¹⁹ as implemented in the EXPO2014.²⁰ Simulated annealing method was performed with EXPO2014, using one zinc, three chloride ions and one proflavine cation per asymmetric unit. Ten runs for simulated annealing trial were set, and a cooling rate (defined as the ratio T_n/T_{n-1}) of 0.95 was used. A Rietveld refinement (Fig. ESI-6) was subsequently performed with TOPAS 5.0,²¹ treating the proflavine molecule as a rigid body. Structural details are listed in table SI-1.

Single crystal X-ray diffraction. Single Crystal data for **2** as well as for PF and for [HPF]Cl·2H₂O were collected at room temperature with an Oxford Diffraction X'Calibur equipped with a graphite monochromator and a CCD detector. Mo-K α radiation (λ = 0.71073 Å) was used. Unit cell parameters for both complexes discussed herein are reported in Table S-1. The structure was solved by the Intrinsic Phasing methods and refined by least squares methods against F^2 using SHELXT-2016²² and SHELXL-2018²³ with Olex2 interface.²⁴ Non-hydrogen atoms were refined anisotropically. H_{CH} atoms were added in calculated positions; H_{OH} and H_{NH} atoms were either located from a Fourier map or added in calculated positions and refined riding on their respective carbon, nitrogen or oxygen atoms. The software Mercury 4.3²⁵ was used for graphical representations and for powder patterns simulation on the basis of single crystal data. Crystal data can be obtained free of charge from the Cambridge Crystallographic Data Centre via

<https://www.ccdc.cam.ac.uk> and have been allocated the accession numbers CCDC 2081498-2081501.


Differential Scanning Calorimetry (DSC). DSC measurements were performed for PF·H₂O, ZnCl₃(HPF) (**1**) and [HPF]₂[ZnCl₄]·H₂O (**2**) with a Perkin–Elmer Diamond. The samples (3–5 mg) were placed in sealed aluminium pans, and heating was carried out at 5 °C min⁻¹.

Thermogravimetric analysis (TGA). TGA measurements for PF·H₂O, ZnCl₃(HPF) (**1**) and [HPF]₂[ZnCl₄]·H₂O (**2**) were performed using a Perkin–Elmer TGA7 in the temperature range 25–450 °C under an N₂ gas flow, at a heating rate of 5 °C min⁻¹.

Antimicrobial Activity. Antimicrobial efficacy was assessed similarly to previous work¹⁰. Inoculation from frozen stocks of each of the three bacterium species strains were cultured in test tubes prepared with 2 mL of Luria-Bertani (LB) and incubated at 37°C for 16hrs. These cultures were then used to inoculate spread plates (for zone of inhibition and contact killing). LB agar plates were spread inoculated with 100 µL of overnight culture and were then allowed to dry while disks were prepared. Antimicrobial filter disks (Oxoid Basingstoke Hants, UK Lot# 1872714) were inserted into metal salt or crystal solutions/slurries of 25mg/mL using sterile tweezers to soak and adsorb materials. Disks were exposed for 1-hour with inversions every 15-min. Disks were then placed on the spread plates, all plates received a disk of AgNO₃ (also prepared from 25 mg/mL) as the internal control. Plates were incubated overnight at 37°C prior to photography and measuring the zone of inhibition by average diameter (mm). The zones of inhibition were ratioed to the zone of AgNO₃ control on each plate to remove plate to plate variances. For contact killing efficacy a pre-grown spread plate received disks to the surface of the bacteria growth lawn and left for 24hrs and then removed to observe clearing of the bacterial growth due to cell lysis (as well as swabbing underneath the disk to see if any exposed bacteria could recover).

Results and Discussion

Proflavine (PF), obtained as a free base from the commercial sulphate salt (see Experimental), was co-crystallized with ZnCl₂ both via mechanochemistry (in the form of its chloride salt) and from solution in 1:1 and 2:1 stoichiometric ratios (see Scheme 2), yielding the neutral, anhydrous complex ZnCl₃(HPF) (**1**) and the hydrated salt [HPF]₂[ZnCl₄]·H₂O (**2**), both containing the proflavinium cation (HPF)⁺, i.e. proflavine in its monoprotonated form (see Scheme 1). Crystallization from solution yielded higher purity target products, which were subsequently utilized for the investigation of the antimicrobial activity. It should be stressed here that the term co-crystallization, in this paper as in other related studies,¹⁰ is used to emphasize that the products are obtained via direct mixing of solid compounds that form stable crystalline phases at ambient conditions and that the target of the investigation is the behaviour of the crystalline products in comparison with the crystalline phases of the separate components (*vide infra*).



Scheme 2. Different reaction pathways for the synthesis of ZnCl₃(HPF) (**1**) and [HPF]₂[ZnCl₄]·H₂O (**2**).

Single crystals of anhydrous proflavine PF were grown directly from polycrystalline PF·H₂O upon dehydration at ca. 100 °C. Figure 1 shows a photograph of the yellow crystals of PF growing from the powder of PF·H₂O while undergoing dehydration under the microscope.




Figure 1. Yellow crystals of anhydrous proflavine, obtained directly upon dehydration of PF·H₂O under the microscope during hot-stage heating to 100°C.

Its structure was determined from single crystal X-ray diffraction data (see ESI) and is characterized by the double herring-bone motif shown in Figure 2, where pairs of PF molecules are stacked along the *b*-axis direction.




Figure 2. (Top) "double" herring-bone pattern in anhydrous PF, and (bottom) front/side views evidencing the C-H...π interactions within a pair of facing molecules.

This arrangement is reminiscent of the one observed in crystalline PF·H₂O (PROFLV), but in this last crystal a simple

herring-bone pattern is present. In both crystals (see inlets in Figures 2 and 3) the PF molecules within a pair are facing each other so as to maximize the number of C-H $\cdots\pi$ interactions.




Figure 3. (Top) Herring-bone pattern of proflavine molecules in the monohydrated free base PF·H₂O (PROFLV) (water molecules not shown for clarity), and (bottom) front/side views evidencing the C-H $\cdots\pi$ interactions, analogously to what observed in crystalline PF.

Single crystals of [HPF]Cl·2H₂O were also recovered in one case from the crystallization batch of [HPF]₂[ZnCl₄]·H₂O (**2**) and were subjected to a data collection revealing the unexpected formation of a novel hydrochloride form of PF. It is interesting to note that in this solid, analogously to what observed for the known dichloride salt [H₂PF]Cl₂·2H₂O (PROFLC), the protonation of the acridine nitrogen, and the concomitant presence of good hydrogen bond acceptors – the chloride ion and the water molecule – favor the formation of π - π stacking arrangements of the aromatic units within the crystal, as shown in Figure 4.




Figure 4. Comparison of the π -stacking arrangements of aromatic mono- and di-cations in the monochloride [HPF]Cl·2H₂O (top) and dichloride [H₂PF]Cl₂·2H₂O (PROFLC) (bottom) proflavine salts. For sake of clarity the cation layers are shown on the right-hand side.

The reaction of proflavine with ZnCl₂ in a 1:1 stoichiometric ratio (see experimental) yields the complex ZnCl₂(HPF) (**1**), which contains the ligand (HPF)⁺, i.e. monoprotonated proflavine. Figure 5 shows how ZnCl₂(HPF) molecules are piled along the crystallographic *c*-axis, with short interplanar distances of 3.30(1) and 3.37(1) Å.




Figure 5. (a) Projection in the *ab*-plane of crystalline ZnCl₂(HPF) (**1**). The molecules are arranged in piles along the *c*-axis direction, with short interplanar distances among the aromatic moieties (b).

Reaction of proflavine with ZnCl₂ in a 2:1 stoichiometric ratio (see experimental) yields the hydrated molecular salt [HPF]₂ZnCl₄·H₂O (**2**), which contains monoprotonated proflavine as a counterion, instead of coordinated ligand as in compound **1**. Figure 6 shows how pairs of proflavinium cations are π -stacked in the crystal, with pairs arranged in a herring-bone fashion; interplanar distances are 3.34(1) and 3.41(1) Å (see fig. 6).




Figure 6. Projection down the crystallographic *b*-axis of crystalline [HPF]₂[ZnCl₄]·H₂O (**2**), showing the herring-bone pattern of HPF⁺ cationic pairs (a) and the π -stacking arrangement of the cations within each pair (b; compare with crystalline **1** in Fig. 5). (Grey and orange spheres represent the carbon atoms belonging to the two independent molecules)

A standard antimicrobial disk-diffusion approach²⁶ was used to evaluate relative antimicrobial activity. Both proflavine and zinc are antimicrobial and the question here is if they would retain their antimicrobial activity in a co-crystal. Rather than reporting absolute zone of inhibition of growth, the amount of inhibition was ratioed for comparison to AgNO₃ (Figure 7). Silver is the most established metal-based antimicrobial²⁷ and thus is an excellent comparator to evaluate new formulations. Under the media conditions used here, AgNO₃ gives minimal inhibitory concentration value of 0.125 mM towards all three bacterial strains used here.²⁸ We see that ZnCl₂ has similar efficacy as AgNO₃ to *P. aeruginosa*, but slightly better efficacy towards *E. coli* and best for *S. aureus*. Proflavine is a planar molecule that effectively intercalates into DNA as its mode of toxicity, making it an effective antimicrobial antiseptic and potential anticancer agent.²⁹ Proflavine shows higher antimicrobial activity than silver in our assays. Combining the two compounds shows a 50 to 125% better efficacy than AgNO₃ towards all three of the pathogen indicator strains we tested. Additionally, all compounds had contact killing against all three strains. This was evaluated by placing the compound impregnated disks onto a

lawn of live bacteria and assessing the ability to kill the bacterial in contact. This data demonstrates that the mixture as a crystal did not decrease the biocidal activity of the compounds and potentially enhances them, which was unexpected and somewhat remarkable. Given that the crystal mixtures by weight would actually have less proflavine by moles, the data implies the presence of the Zn enhances the antimicrobial efficacy of proflavine more than what one interprets from Figure 7.




Figure 7. Fold antimicrobial activity compared to AgNO₃ (the value of 1.00 is equal efficacy as silver nitrate). Data from 3 independent biological trials (2 technical trials each) are given, variance between trials was removed through ratioing to a control on each plate (silver nitrate) which leads to negligible differences in fold activity.

Conclusions

The increasing concern in the development of antimicrobial resistance is motivating the quest for new materials to be used in the battle against pathogens. A promising approach is that of using co-crystallization to synthesise new materials and/or to enhance the properties of active molecules. With this idea in mind we have prepared by both solution and solid-state methods and structurally characterized two novel compounds of the antibacterial proflavine with ZnCl₂, namely ZnCl₃(HPF) (**1**) and [HPF]₂[ZnCl₄]·H₂O (**2**). Interestingly, **1** can be obtained mechanochemically as the unique product when starting from [HPF]Cl·2H₂O while reaction in solution from PF·H₂O and ZnCl₂ yields **1** or **2** depending on whether a 1:1 or 2:1 stoichiometric ratio of the reactants is used. The fact that mechanochemical and solution synthesis may yield different products is not surprising³⁰ and has been observed in several cases. In terms of antimicrobial activity the two compounds appear to be from 1.5 to 2 times more efficient towards the pathogen indicator strains with respect to the reagents and towards AgNO₃ used as a standard of metal antimicrobial activity. We envisage the use of our compounds as coating materials in the prevention of infectious disease transfer or microbial fouling. The challenges that exist is producing a crystal that releases the active ingredients at a level that sustains antimicrobial properties and that is stable to the physical manipulation and use of the material that has been coated. This opens avenues for

development of unique metal chelates and organo-metal compounds for AMB applications. DOI: 10.1039/D1CE00612F

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This material is based upon O.S. D.B., F.G. work supported by the University of Bologna (RFO scheme). NSERC supported the contribution of R.J.T.

R.J.T. thanks Dylan Greening for his assistance. The help of Dr. Lucia Casali (structure solution from X-ray powder data) and Dr. Katia Rubini (DSC/TGA) is gratefully acknowledged. The contribution of Marzia Guerrini as a part of her master thesis under D.B. supervision is acknowledged.

Notes and reference

- S. B. Levy and M. Bonnie, *Nat. Med.*, 2004, **10**, S122–S129
- E. D. Brown and G. D. Wright, *Nature*, 2016, **529**, 336–343.
- L. M. Streicher, *J. Glob. Antimicrob. Resist.*, 2021, **24**, 285–295.
- G. R. Desiraju, *Angew. Chemie Int. Ed.*, 2007, **46**, 8342–8356.
- Ö. Almarsson and M. J. Zaworotko, *Chem. Commun.*, 2004, **0**, 1889–1896.
- J. Wouters, L. Quéré, *Pharmaceutical salts and co-crystals*, Royal Society of Chemistry, 2011.
- N. Schultheiss and A. Newman, *Cryst. Growth Des.*, 2009, **9**, 2950–2967.
- M. Wainwright, *J. Antimicrob. Chemother.*, 2001, **47**, 1–13.
- M. C. Sulavik, C. Houseweart, C. Cramer, N. Jiwani, N. Murgolo, J. Greene, B. Didomenico, K. J. Shaw, G. H. Miller, R. Hare and G. Shimer, *Antimicrob. Agents Chemother.*, 2001, **45**, 1126–1136.
- O. Shemchuk, D. Braga, F. Grepioni and R. J. Turner, *RSC Adv.*, 2020, **10**, 2146–2149.
- O. Shemchuk, S. D'Agostino, C. Fiore, V. Sambri, S. Zannoli, F. Grepioni and D. Braga, *Cryst. Growth Des.*, 2020, **20**, 6796–6803.
- S. P. Gopi, S. Ganguly and G. R. Desiraju, *Mol. Pharm.*, 2016, **13**, 3590–3594.
- R. J. Turner, *Microb. Biotechnol.*, 2017, **10**, 1062–1065.
- J. A. Lemire, J. J. Harrison and R. J. Turner, *Nat. Rev. Microbiol.*, 2013, **11**, 371–384.
- J. W. Alexander, *History of the medical use of silver. Surg Infect (Larchmt)*, 2009, **10**, 289–292.
- A. S. Abd-El-Aziz, C. Agatemor and N. Etkin, *Biomaterials*, 2017, **118**, 27–50.
- A. Achari and S. Neidle, *Acta Crystallogr. Sect. B Struct. Crystallogr. Cryst. Chem.*, 1976, **32**, 2537–2539.
- S. K. Obendorf, H. L. Carrell and J. P. Glusker, *Acta Crystallogr. Sect. B Struct. Crystallogr. Cryst. Chem.*, 1974, **30**, 1408–1411.
- A. Altomare, C. Giacobbo, A. Guagliardi, A. G. G. Moliterni, R. Rizzi and P. E. Werner, *J. Appl. Crystallogr.*, 2000, **33**, 1180–1186.
- A. Altomare, C. Cuocci, C. Giacobbo, A. Moliterni, R. Rizzi, N. Corriero and A. Falcicchio, *J. Appl. Crystallogr.*, 2013, **46**, 1231–1235.
- A. A. Coelho, *J. Appl. Crystallogr.*, 2018, **51**, 210–218.
- G. M. Sheldrick, *Acta Crystallogr. Sect. A Found. Crystallogr.*, 2015, **71**, 3–8.
- G. M. Sheldrick, *Acta Crystallogr. Sect. C Struct. Chem.*, 2015, **71**, 3–8.

ARTICLE

Journal Name

- 24 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339–341.
- 25 C. F. MacRae, I. Sovago, S. J. Cottrell, P. T. A. Galek, P. McCabe, E. Pidcock, M. Platings, G. P. Shields, J. S. Stevens, M. Towler and P. A. Wood, *J. Appl. Crystallogr.*, 2020, **53**, 226–235.
- 26 M. Balouiri, M. Sadiki and S. K. Ibensouda, *J. Pharm. Anal.*, 2016, **6**, 71–79.
- 27 J. S. Möhler, W. Sim, M. A. T. Blaskovich, M. A. Cooper and Z. M. Ziora, *Biotechnol. Adv.*, 2018, **36**, 1391–1411.
- 28 A. Pormohammad and R. J. Turner, *Antibiotics*, 2020, **9**, 853.
- 29 V. M. Hridya, J. T. Hynes and A. Mukherjee, *J. Phys. Chem. B*, 2019, **123**, 10904–10914.
- 30 S. L. James, C. J. Adams, C. Bolm, D. Braga, P. Collier, T. Frišćić, F. Grepioni, K. D. M. Harris, G. Hyett, W. Jones, A. Krebs, J. Mack, L. Maini, A. G. Orpen, I. P. Parkin, W. C. Shearouse, J. W. Steed, D. C. Waddell, D. C. *Chem. Soc. Rev.* **2012**, **41**, 413–447.

View Article Online
DOI: 10.1039/D1CE00612F